Oramed Pharmaceuticals Inc.

Director's Dealing • Jul 1, 2019

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

* 1. Name and Address of Reporting Person Gabay Avraham						2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ ORMP ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director Officer (give title below) CFO, Treasurer and Secretary		10% Owner
(Last) (First) (Middle) HI-TECH PARK 2/4 GIVAT-RAM						3. Date of Earliest Transaction (Month/Day/Year) 06/17/2019							X			Other (specify below)
P.O. BOX 39098 (Street)						4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person
JERUSALEM (City)		L3 (State)		91390 (Zip)											Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)						2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	and 5)	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4				5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
							Code	V	(A) or Amount (D)		Price		Reported Transaction(s) (Instr. 3 and 4)
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of	2.		3. Transaction	3A. Deemed		4.		5. Number 6. Date Exercisable and				7. Title and		8. Price	9. Number of		10.	11. Nature

Derivative Security (Instr. 3)		Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year)	Transaction Code (Instr. 8)		of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date (Month/Day/Year)		Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		of Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect Beneficial Ownership (Instr. 4)
					Code		V (A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
	Stock Option (right to buy)	\$3.55	06/17/2019		A		33,146		(1)	06/17/2029	Common Stock	33,146	\$0	33,146	D

Explanation of Responses:

1. The Stock Option will vest in 4 installments as follows: 5,396 shall vest on December 31, 2019; and 9,250 shall vest on each of December 31, 2020, December 31, 2021 and December 31, 2022.

/s/ Avraham Gabay 06/27/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.